Back to top

Image: Bigstock

Nektar Therapeutics

Read MoreHide Full Article

Nektar, a commercial biopharmaceutical company, is focused on the development of drugs utilizing PEGylation and advanced polymer conjugate technology platforms. The company received a huge boost when Movantik became the first oral PAMORA to gain approval in both the U.S. and the EU. Nektar stands to receive significant sales milestone and royalty opportunity for Movantik under the AstraZeneca license agreement, which is expected to boost its financial position significantly. Moreover, if the company’s other partnered programs are successful, they could contribute to the company’s royalty streams as early as 2017. However, Nektar relies heavily on its partners for top-line growth. Stiff competition is another concern. Nektar also has a robust pipeline. It has several pipeline-related updates coming up over the next several quarters, which could act as catalyst. Any hiccup could pull down the stock significantly.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Nektar Therapeutics (NKTR) - free report >>

Published in